more of the same. todays presentation was a non-event really, it would've been more of an event if DRTX hadnt published these results. this is standard pre-FDA biotech procedure. its been recovering nicely over the last few weeks form the mid upper 7s but still hasnt reached the pps prior to the drop. perhaps with the PR of the actual FDA filing may see a pop. but with this low low volume its really making me think its not really on anybody's radar. TSRX was getting massive attention and volume in its BO run up, obviously on insider info, but with this anemic price action it doesnt say much. i have taken some profits at the intra day highs over the last couple days, dont want to see another drop. dont even think i would buy back on any significant dips, just hold long.
I think you might be short. This is great news, both studies met primary and secondary end-points. This may get scooped up by big Pharma faster than anyone realizes. It is not a non event to meet your PHIII trial end-points. Shorts will suffer greatly.